We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Partner Therapeutics Lands $35 Million DOD Contract for Leukine as COVID-19 Treatment
Partner Therapeutics Lands $35 Million DOD Contract for Leukine as COVID-19 Treatment
Massachusetts-based Partner Therapeutics has secured a $35 million contract from the Department of Defense for clinical trials of inhaled Leukine (sargramostim) for the treatment of COVID-19 patients with acute hypoxemia.